AU779869B2 - Pulmonary administration of dry powder formulations for treating infertility - Google Patents

Pulmonary administration of dry powder formulations for treating infertility Download PDF

Info

Publication number
AU779869B2
AU779869B2 AU40820/00A AU4082000A AU779869B2 AU 779869 B2 AU779869 B2 AU 779869B2 AU 40820/00 A AU40820/00 A AU 40820/00A AU 4082000 A AU4082000 A AU 4082000A AU 779869 B2 AU779869 B2 AU 779869B2
Authority
AU
Australia
Prior art keywords
composition
fsp
cys
thr
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU40820/00A
Other languages
English (en)
Other versions
AU4082000A (en
Inventor
Darrel Lavern Allen
David B. Bennett
Hi-Shi Chiang
Joanne Greene
Benjamin Lee Hughes
Sudha Nagarajan
John S Patton
William David Roeder
Mary Stiff-Torvik
Cheryl L.M. Stults
Geraldine Venthoye
Ronald Keith Wolff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Priority claimed from PCT/US2000/009869 external-priority patent/WO2000061178A1/en
Publication of AU4082000A publication Critical patent/AU4082000A/en
Assigned to NEKTAR THERAPEUTICS, ELI LILLY AND COMPANY reassignment NEKTAR THERAPEUTICS Alteration of Name(s) of Applicant(s) under S113 Assignors: ELI LILLY AND COMPANY, INHALE THERAPEUTICS SYSTEMS, INC.
Assigned to NEKTAR THERAPEUTICS reassignment NEKTAR THERAPEUTICS Alteration of Name(s) of Applicant(s) under S113 Assignors: ELI LILLY AND COMPANY, NEKTAR THERAPEUTICS
Application granted granted Critical
Publication of AU779869B2 publication Critical patent/AU779869B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU40820/00A 1999-04-13 2000-04-13 Pulmonary administration of dry powder formulations for treating infertility Ceased AU779869B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12912199P 1999-04-13 1999-04-13
US60/129121 1999-04-13
US13009999P 1999-04-20 1999-04-20
US60/130099 1999-04-20
PCT/US2000/009869 WO2000061178A1 (en) 1999-04-13 2000-04-13 Pulmonary administration of dry powder formulations for treating infertility

Publications (2)

Publication Number Publication Date
AU4082000A AU4082000A (en) 2000-11-14
AU779869B2 true AU779869B2 (en) 2005-02-17

Family

ID=26827234

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40820/00A Ceased AU779869B2 (en) 1999-04-13 2000-04-13 Pulmonary administration of dry powder formulations for treating infertility

Country Status (7)

Country Link
US (1) US7112341B1 (enExample)
EP (1) EP1169053A1 (enExample)
JP (1) JP2002541213A (enExample)
AU (1) AU779869B2 (enExample)
CA (1) CA2369262A1 (enExample)
HK (1) HK1042234A1 (enExample)
TW (1) TWI277425B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2343124T3 (es) * 1999-10-29 2010-07-23 Novartis Ag Composiciones de polvo seco con dispersabilidad mejorada.
EP1631496B1 (en) * 2003-04-28 2014-02-26 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
JP4933439B2 (ja) * 2004-11-09 2012-05-16 アレス トレーディング ソシエテ アノニム Fshの精製方法
EP1960419B1 (en) * 2005-12-09 2016-03-16 Ares Trading S.A. Method for purifying fsh or a fsh mutant
US7966746B2 (en) * 2006-04-24 2011-06-28 Medical Instill Technologies, LLC Needle penetrable and laser resealable lyophilization method
JP2010533181A (ja) * 2007-07-13 2010-10-21 アボツト・バイオテクノロジー・リミテツド TNFα阻害剤の肺投与のための方法及び組成物
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20110002931A1 (en) 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
US9180186B2 (en) 2010-01-11 2015-11-10 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
EP2563813B1 (en) 2010-04-30 2015-08-26 Alexion Pharmaceuticals, Inc. Anti-c5a antibodies and methods for using the antibodies
CA2842276C (en) * 2011-08-02 2020-11-24 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition of oxidised avidin suitable for inhalation
RU2018132561A (ru) 2012-07-30 2018-11-02 Трофоген Инк. Суперагонисты гликопротеинового гормона длительного действия
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
MX2016005973A (es) 2013-11-05 2016-11-14 Trophogen Inc Superagonistas de acción prolongada de la hormona de glicoproteína.
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
WO2017205101A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
FI3658184T3 (fi) 2017-07-27 2023-11-30 Alexion Pharma Inc Korkean pitoisuuden omaavia anti-c5-vasta-aineformulaatioita
JP7518764B2 (ja) 2017-10-26 2024-07-18 アレクシオン ファーマシューティカルズ, インコーポレイテッド 発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019231983A1 (en) 2018-05-31 2019-12-05 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群(aHUS)の治療のための抗C5抗体の用量および投与
JP7538723B2 (ja) 2018-06-28 2024-08-22 アレクシオン ファーマシューティカルズ, インコーポレイテッド 抗c5抗体の産生方法
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
AU2019370295A1 (en) 2018-10-30 2021-06-03 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
JP2023504208A (ja) 2019-12-09 2023-02-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼポリペプチド及びその使用方法
MX2023004621A (es) * 2020-10-23 2023-06-06 Alexion Pharma Inc Método de control del contenido total de ácido siálico (ctas) durante la fabricación de fosfatasa alcalina.
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000128A1 (en) * 1993-06-24 1995-01-05 Astra Aktiebolag Compositions for inhalation
WO1996019207A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Powder formulations containing melezitose as a diluent
WO1997041833A1 (en) * 1996-05-08 1997-11-13 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2224175B1 (enExample) 1973-04-04 1978-04-14 Isf Spa
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
US4234571A (en) 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
HU185535B (en) 1982-05-25 1985-02-28 Mta Koezponti Hivatala Process for preparing new gonadoliberin derivatives
GB8314308D0 (en) 1983-05-24 1983-06-29 Matburn Holdings Ltd Medical administration devices
US5156957A (en) 1983-11-02 1992-10-20 Genzyme Corporation Follicle stimulating hormone
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US5639639A (en) 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
DE3486469T2 (de) 1983-11-02 1999-04-15 Applied Research Systems Ars Holding N.V., Curacao Herstellung heterodimirer menschlicher Fruchtbarkeitshormone
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
EP0229810B1 (en) 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection of proteins and the like
JPS6447952A (en) * 1987-05-06 1989-02-22 Saibaafuruua Inc Immunoassay, reagent used therefor and making thereof
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
DE69029799T2 (de) 1989-02-21 1997-05-28 Washington University, St. Louis, Mo. Modifizierte formen von fortpflanzungshormonen
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5270057A (en) 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
IT1243344B (it) 1990-07-16 1994-06-10 Promo Pack Sa Inalatore plurimonodose per medicamenti in polvere
EP0940154B1 (en) 1991-07-02 2007-04-18 Nektar Therapeutics Device for delivering aerosolized medicaments
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
IT1250075B (it) 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5320094A (en) 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US6238890B1 (en) * 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
FR2754450B1 (fr) 1996-10-11 1998-12-31 3X Engineering Materiau support de microcapsules
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US5990288A (en) * 1997-10-21 1999-11-23 Vitro Diagnostics, Inc. Method for purifying FSH
US6573238B2 (en) 1997-11-07 2003-06-03 Chiron Corporation Method for producing sustained-release formulations
JP4719357B2 (ja) 1998-07-23 2011-07-06 アレス トレイディング ソシエテ アノニム Fsh及びfsh変異体の製剤、製品及び方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000128A1 (en) * 1993-06-24 1995-01-05 Astra Aktiebolag Compositions for inhalation
WO1996019207A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Powder formulations containing melezitose as a diluent
WO1997041833A1 (en) * 1996-05-08 1997-11-13 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use

Also Published As

Publication number Publication date
TWI277425B (en) 2007-04-01
JP2002541213A (ja) 2002-12-03
US7112341B1 (en) 2006-09-26
HK1042234A1 (zh) 2002-08-09
AU4082000A (en) 2000-11-14
CA2369262A1 (en) 2000-10-19
EP1169053A1 (en) 2002-01-09

Similar Documents

Publication Publication Date Title
AU779869B2 (en) Pulmonary administration of dry powder formulations for treating infertility
WO2000061178A1 (en) Pulmonary administration of dry powder formulations for treating infertility
EP2152245B1 (en) Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP1462096B1 (en) Methods and compositions for pulmonary delivery of insulin
AU2014290438B2 (en) Heat-stable dry powder pharmaceutical compositions and methods
JP3764174B2 (ja) 肺用組成物において使用するための亜鉛非含有のインスリン結晶
KR101662631B1 (ko) Fsh의 액체 포뮬레이션
EP0951911A2 (en) Method for administering aspb28-human insulin
US20080031966A1 (en) Sustained release compositions for delivery of pharmaceutical proteins
JP2008163033A (ja) エアゾール化医薬の肺への送達
CN101784280A (zh) 药物多肽干粉气溶胶制剂及制备方法
EP1418890A1 (en) Propellant-based microparticle formulations
US20090203576A1 (en) Methods and compositons for pulmonary delivery of insulin
JP2005520847A (ja) 肺投与用hGH(ヒト成長ホルモン)製剤
EP1424066B1 (en) Dry compositions comprising hydrophobic stabilisers
WO2001093837A2 (en) Protein powder for pulmonary delivery
EP2036572A1 (en) Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
RU2175556C2 (ru) Способы и композиции для легочной доставки инсулина
KR20130055665A (ko) 소 과립구 콜로니 자극 인자 및 그의 변이체를 위한 제제
US20040214747A1 (en) Method for administering monomeric insulin
HK1065248A (en) Methods and compositions for pulmonary delivery of insulin
HK1024860A (en) Method for administering aspb28-human insulin

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NEKTAR THERAPEUTICS, ELI LILLY AND COMPANY

Free format text: THE FORMER OWNER WAS: INHALE THERAPEUTICS SYSTEMS, INC., ELI LILLY AND COMPANY

PC1 Assignment before grant (sect. 113)

Owner name: NEKTAR THERAPEUTICS

Free format text: THE FORMER OWNER WAS: NEKTAR THERAPEUTICS, ELI LILLY AND COMPANY